Trial Profile

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirzepatide (Primary) ; Dulaglutide
Indications Cardiovascular disorders; Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms SURPASS-CVOT
Sponsors Eli Lilly and Company

Most Recent Events

25 Apr 2024 Planned End Date changed from 17 Oct 2024 to 1 Jun 2025.
25 Apr 2024 Planned primary completion date changed from 17 Oct 2024 to 1 Jun 2025.
25 Sep 2023 Trial design published in the American Heart Journal

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com